The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne.
Recovering Ambulation After Lower Extremity Fracture in Duchenne
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate